TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03596853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive mobilization
Description: Will be applied once a day, 5x/ week, performed into 4 levels: N1 (bridge and rolling for both sides); N2 (transfer training from lying down to sitting on both sides); N3 (sit and stand up from a chair); N4 (running training). According to their functional level, patients will perform, once a day, 8 sets of each movement, alternating 20 seconds of execution with 10 seconds of rest. Patients will be stimulated constantly to perform the movements with the highest possible speed.~If the patient performs adequately within of your level functional level, can will progress in level, if can not progress, there will be an increase in training volume within the level itself. Adequate performance within the functional level means that the patient is able to complete more than eight sets of exercise and does not present increased sensation of pain, present sensation of perceived exertion within the safety limit of the protocol (Borg ≤ 6).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: This group will receive standard usual, which will be monitored, but not protocolised.
Study: NCT02676713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-ovulation Decoction
Description: BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.~All are made into granules.
Study: NCT03107767

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRO-malleol algorithm
Description: An evidence based algorithm for ankle fractures
Study: NCT04877067

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wharton jelly derived mesenchymal stem cell
Description: WJ-MSC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wharton jelly derived mesenchymal stem cell
Description: WJ-MSC
Study: NCT02676713

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pre-ovulation Decoction(placebo)
Description: Composition of maltodextrin, lactose, edible pigment, taste masking agent.
Study: NCT04877067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive electromagnetic stimulation
Description: rEMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive electromagnetic stimulation
Description: rEMS
Study: NCT03029598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03714815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan 10 mg
Description: macitentan 10 mg, film-coated tablet, oral use
Study: NCT01047241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil/ketamine
Description: Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
Study: NCT01502735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DENV-1 PIV, 5 µg
Description: 5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
Study: NCT02676713

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: post-ovulation Decoction(placebo)
Description: Composition of maltodextrin, lactose, edible pigment, taste masking agent.
Study: NCT04597489

Intervention type: PROCEDURE
Intervention: Fractional flow reserve
Description: Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.

Intervention type: PROCEDURE
Intervention: Fractional flow reserve
Description: Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.

Intervention type: PROCEDURE
Intervention: Fractional flow reserve
Description: Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.

Intervention type: PROCEDURE
Intervention: Fractional flow reserve
Description: Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.

Intervention type: PROCEDURE
Intervention: Fractional flow reserve
Description: Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
Study: NCT02404714

Intervention type: DEVICE
Intervention: Iontophoresis sweat test
Description: The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
Study: NCT04597489

Intervention type: PROCEDURE
Intervention: Angiography-only
Description: Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.

Intervention type: PROCEDURE
Intervention: Angiography-only
Description: Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
Study: NCT00800735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alfa-2a
Description: Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
Study: NCT00800735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing \< 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
Study: NCT04345055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of the lumbar fasciae
Description: Treat the lumbar facial with a manual technique

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Introduce in a machine off
Study: NCT02847403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
Study: NCT02951507

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: O T unilateral attachment
Description: O T unilateral attachment system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New design of extracoronal attachment system
Description: O T unilateral attachment
Study: NCT01151657

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules containing maltodextrin
Study: NCT04485702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: 2mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Injectable Product
Description: 6mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MELT-100
Description: midazolam 3mg and ketamine 25mg SL tablet
Study: NCT04753775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aloe vera gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aloe vera gel
Study: NCT00727116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA Abusive Head Trauma Prevention Program: State-wide
Description: Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA Abusive Head Trauma Prevention Program: State-wide
Description: Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA Abusive Head Trauma Prevention Program Booster: Central PA
Description: All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
Study: NCT01084889

Intervention type: DEVICE
Intervention: surgical mesh implantation (TiLOOP® Total 6)
Description: The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The surgical mesh TiLOOP® Total 6 is placed transvaginal by the aid of TiLOOP® surgical instruments to place the mesh arms.
Study: NCT02768207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 mg tablets (three 20 mg tablet) orally OD for 21 consecutive days (Days 1 to 21), followed by a 7 day break (Days 22 to 28); in each 28-day cycle of treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive vemurafenib 960 mg tablets (four 240 mg tablet) orally BID from Day 1 to Day 28 of each 28-day cycle of the treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
Study: NCT04879407

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Any rivaroxaban dispensing claim is used as the exposure group

Intervention type: DRUG
Intervention: Warfarin
Description: Any warfarin dispensing claim is used as the reference group
Study: NCT02234349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreas kidney transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kidney transplantation
Study: NCT00700206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezatiostat Hydrochloride
Description: Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezatiostat Hydrochloride
Description: Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle.
Study: NCT01885988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
Study: NCT00671086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
Study: NCT05098314

Intervention type: OTHER
Intervention: Personalized interventions regarding the Cicat-Occitanie network
Description: First of all, healthcare professionals from EHPAD in the intervention arm were invited by email to answer a closed questionnaire. It was built by the authors, on Google forms, and consisted of 11 questions divided into 2 sections.~Section 1 collected data about the participants. In section 2, they were asked to score from 0 to 4 (ranging from not at all to a lot ) the various obstacles to teleconsultations reported by the literature.
Study: NCT04501432

Intervention type: OTHER
Intervention: No intervention
Description: This study does not include an intervention
Study: NCT00512564

Intervention type: OTHER
Intervention: Laboratory analyses of iron overload
Description: Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
Study: NCT04929964

Intervention type: PROCEDURE
Intervention: MRM , Toilet Mastectomy , BCS
Description: MRM , modified radical mastectomy : removing breast and axilla toilet mastectomy : palliative removal of tumor load BCS ,Breast conservative surgery
Study: NCT01072526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euphrasia-based homeopathic therapy
Description: ophthalmic solution; 1 drop both eyes twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclosporin solution
Description: Cyclosporin solution; 1 drop both eyes twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin solution
Description: Cyclosporin solution; 1 drop both eyes twice daily
Study: NCT01816295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Solution
Description: Administered topically to axillae.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: Administered topically to axillae.
Study: NCT03612024

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: a standardized questionnaire was sent to all participants

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: a standardized questionnaire was sent to all participants
Study: NCT01076010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
Study: NCT03545048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet based exercises
Description: Exercises for knee OA (online- digital health)
Study: NCT02149459

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial brain re-irradiation.
Description: Partial brain re-irradiation to a dose of 30-35Gy delivered over 2 weeks (10 fractions).
Study: NCT03604237

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Targeted group
Description: Forceps biopsy is taken after surface evaluation of the large colorectal tumors.
Study: NCT04124692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra Aesthetic new dilution
Description: Treatment of cheek wrinkles
Study: NCT02149459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Different cohorts will receive no, low dose or higher dose metformin.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low carbohydrate diet
Description: Under close supervision of a dietician, patients will receive a low carbohydrate diet, enriched as necessary with medium chain triglyceride (MCT) supplements.
Study: NCT04468373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WA-NG (NG-IMT) Telescope Prothesis
Description: The WA-NG telescope prosthesis is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
Study: NCT03976336

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Identical Placebo
Description: 500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
Study: NCT00929214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Therapy
Description: Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Therapy
Description: Surgery and/or Radiation Therapy~With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks.
Study: NCT04643015

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Briefly, new MRI sequences will be used on a patient who is undergoing a scheduled, clinically necessary MRI exam. Any new research sequence will be scanned in addition to the clinically required sequences and will not interfere with the clinical scan other than requiring five to ten minutes of additional table time. There will be no invasive measures under this protocol.
Study: NCT02823678

Intervention type: PROCEDURE
Intervention: Pancreatectomy
Description: Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.
Study: NCT02353039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC6101A 37.5mg
Description: Administer 12.5mg of GC6101A t.i.d for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC6101A 75mg
Description: Administer 25mg of GC6101A t.i.d for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC6101A 150mg
Description: Administer 50mg of GC6101A t.i.d for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer placebo t.i.d for 2 weeks
Study: NCT02855320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led self-management education intervention
Description: A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
Study: NCT02325947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand exoskeleton, brain-computer interface (BCI),
Description: Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: hand exoskeleton, sham BCI
Description: Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
Study: NCT05684601

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar surgery
Description: It was extracted one impacted mandibular third molar per patient with piezoelectric or rotating drills device
Study: NCT00534001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT04228458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Imaging
Description: Testing the effectiveness of using a Thermal Imaging camera in participants with Juvenile Arthritis.
Study: NCT03885700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program for 2 months
Description: The intervention was suggested based on the recommendations for adolescents' healthy diet and physical activity, it was derived from the 2008 Physical Activity Guidelines for Americans and Dietary Guidelines for Americans, 2010 by the U.S. HHS, Physical activity guidelines for children and adolescents by CPS 2012. The Food Guide Pyramid by the USDA, Nutrition \&Healthy Eating by Mayo clinic \& CDC website. The program was modified according to the age of the child. This plan was typically pursued in a School-based Intervention to Promote Healthy Lifestyles in Sousse, Tunisia, by Harrabi et al. The 1st month covered the healthy diet \& the 2nd month covered the physical activity as follow:~* 1st \& 5th week: A 60-minutesession in health education.~* 2nd \& 6th week: Group counselling.~* 3rd \& 7th week: Students were divided into 8 groups \& each group was asked to make presentation about a task related to the topic.~* 4th \& 8th week: Discussing the presentation.
Study: NCT01803633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheddar cheese
Description: Tillamook medium cheddar cheese brand

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegan cheese
Description: Daiya brand vegan cheese